

# 8<sup>th</sup> INTERNATIONAL SYMPOSIUM ON STEM CELL THERAPY & CARDIOVASCULAR INNOVATIONS



[www.cardiovascularcelltherapy.com](http://www.cardiovascularcelltherapy.com)

Symposium Director: Francisco Fernández –Avilés

## SCIENTIFIC AGENDA




MADRID. SPAIN, JUNE 9<sup>th</sup> - 10<sup>th</sup> 2011

SALÓN DE ACTOS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) C/ SERRANO 117, 28006 MADRID







<b>1</b>	<b>SCIENTIFIC AGENDA</b>	
<b>2</b>	<b>ACCREDITATION</b>	
<b>3</b>	<b>ORGANIZATION</b>	Direction International Scientific Advisory Board Executive Local Committee
<b>4</b>	<b>EDUCATIONAL OBJECTIVES</b>	
<b>5</b>	<b>FACULTY</b>	Meeting Venue
<b>6</b>	<b>GENERAL INFORMATION</b>	Date Official languages
<b>7</b>	<b>WEBSITE</b>	



# WEDNESDAY, 8<sup>th</sup> June 2011

## PRE-SYMPOSIUM ACTIVITIES

---

12:30 - 15:00 First meeting of the International Enterprise for the production of Bioartificial organs and tissues. The BIO-ART project.

Room to be confirmed

Hotel Hesperia Madrid

Paseo de la Castellana, 57

18:00 - 20:00 Meeting of the BAMI group (The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all cause mortality in acute myocardial infarction)

Room to be confirmed

Hotel Hesperia Madrid

Paseo de la Castellana, 57

# THURSDAY, 9<sup>th</sup> June 2011

7:45 - 8:30 **REGISTRATION**

8:30 - 9:00 **WELCOMING**

## 9:00 - 10:00 **OPENING SPECIAL LECTURES**

---

Chairs: John Martin (London, UK)  
María Orera (Madrid, Spain)

9:00 - 9:25 **Genetics in our daily clinical practice**  
William McKenna (London, UK)

9:30 - 9:55 **Personalised Cardiovascular Medicine. Is genetics the answer?**  
Valentin Fuster (New York, USA)

## 10:00 - 11:45 **WHAT'S NEW IN STEM CELL THERAPY FOR CARDIAC REPAIR? - I**

---

Chairs: Manuel Galiñanes (Barcelona, Spain)  
Kai C. Wollert (Hannover, Germany)

Discussants: Bernard Gersh (Rochester, USA)  
Timothy Henry (Rochester, USA)  
Philippe Menasché (Paris, France)  
Emerson Perin (Houston, USA)  
Felipe Prosper (Pamplona, Spain)  
Doris Taylor (Minneapolis, USA)

10:00 - 10:15 **Association between progenitor cells and cardiovascular integrity. What's new?**  
Amir Lerman (Rochester, USA)

10:15 - 10:30 **Original versus Modified cells. What's new?**  
André Terzic (Rochester, USA)

10:30 - 10:45 **Mechanisms of benefit of cells for cardiac repair. What's new?**  
Stefanie Dimmeler (Frankfurt, Germany)

10:45 - 11:00 **Myocardial tissue engineering. What's new?**  
Karen Christman (San Diego, USA)

11:00 - 11:15 **Cells on the shelf. Are allogenic the answer?**  
Dominique Charron (Paris, France)

11:15 - 11:45 **Panel Discussion**

**11:45- 12:15 COFFEE BREAK**

---

**12:15 - 13:50 WHAT'S NEW IN STEM CELL THERAPY FOR CARDIAC REPAIR? - II**

---

Chairs: Manuel Galiñanes (Barcelona, Spain)  
Kai C. Wollert (Hannover, Germany)

Discussants: Bernard Gersh (Rochester, USA)  
Timothy Henry (Rochester, USA)  
Philippe Menasché (Paris, France)  
Emerson Perin (Houston, USA)  
Felipe Prosper (Pamplona, Spain)  
Doris Taylor (Minneapolis, USA)

12:15 – 12:30 **Optimizing tissue delivery and retention. What's new?**  
Warren Sherman (New York, USA)

12:30 – 12:45 **Stem cell therapy for STEMI. The new Pan European proposal.**  
Anthony Marthur (London, UK)

12:45 – 13:00 **Clinical trials. What's new?**  
Stefan Janssens (Leuven, Belgium)

13:00 – 13:15 **Lessons from other organs. What's new?**  
Lilach Lerman (Rochester, USA)

13:15 - 13:30 **Cardiovascular translational research in stem cell therapy.  
The vision of scientific organizations**  
Nabil Dib (San Diego, USA)

13:30 – 13:50 Panel Discussion

**13:50 - 15:00 Lunch and Poster Exhibition**

---

Jury and chair: Philippe Menasche (Paris, France)  
Felipe Prosper (Pamplona, Spain)

In this “Poster Exhibition” research teams involved in the topic of the Symposium will have the opportunity of presenting selected parts of their work to the audience.

A Poster Review Committee will select which the best posters of the session are. At the end of the session, the verdict will be communicated. The winners of the Posters Awards will have to present their work oral presentation the following day in the morning, in the session named “Best Posters Presentation”, when they will receive their prize

**15:00 - 16:30 LATE BREAKING CLINICAL TRIALS IN STEM CELL THERAPY - I**

Chairs: David García-Dorado (Barcelona, Spain)  
Bernard Gersh (Rochester, USA)

Discussants: Stefan Janssens (Leuven, Belgium)  
Philippe Menasché (Paris, France)  
Emerson Perin (Houston, USA)  
Alberto San Roman (Valladolid, Spain)  
José Suárez de Lezo (Cordoba, Spain)  
James T. Willerson (Houston, USA)

15.00 – 15.15 **BMMNCs in acute myocardial infarction: update on TIME and LateTIME and the future of the Cardiovascular Cell Therapy Research Network**

Robert Simari (Rochester, USA)

15.15 – 15.30 **Repair AMI. 5 years and counting**

Andreas Zeiher (Frankfurt, Germany)

15.30 – 15.45 **Selected CD133+ endothelial progenitor cells to create angiogenesis in patients with refractory angina. Preliminary safety results of the PROGENITOR randomized trial**

Pilar Jimenez-Quevedo (Madrid, Spain)

15.45 – 16.00 **Safety and early efficacy findings of SDF-1 for the treatment of chronic heart failure**

Mark S. Penn (Cleveland, USA)

16.00 – 16.30 Panel Discussion

**16:30 - 18:15 SPECIAL THEMED SESSION:  
PULMONARY HYPERTENSION. INNOVATION FOR AN OLD DRAMA**

Chairs: Pilar Escribano (Madrid, Spain)  
James T. Willerson (Houston, USA)

Discussants: Joan Albert Barberá (Barcelona, Spain)  
Luis Alonso Pulpon (Madrid, Spain)  
Javier Bermejo (Madrid, Spain)  
José Cortina (Madrid, Spain)  
Marisa Crespo (A Coruña, Spain)  
Bernard Gersh (Rochester, USA)

16:30 - 16:45 **Pulmonary Hypertension in perspective. The point of view of the expert: Dimensions, concepts, classification and current evidence-based management.**

Miguel Ángel Gómez-Sánchez (Madrid, Spain)

- |               |  |
|---------------|--|
| 16:45 - 17:00 | <b>Scientific basis of pulmonary hypertension treatment. Is there a role for stem cell therapy?</b><br><i>Stephen L. Archer</i> (Chicago, USA) |
| 17:00 - 17:15 | <b>Pulmonary hypertension assessment in 2011. What should we wait from imaging innovation?</b><br><i>Irene M. Lang</i> (Vienna, Austria)       |
| 17:15 - 17:30 | <b>Interventional and surgical modalities of treatment of pulmonary hypertension.</b><br><i>Julio Sandoval-Zárate</i> (Mexico DF, Mexico)      |
| 17:30 - 17:45 | <b>Future perspective for the treatment of Pulmonary Hypertension</b><br><i>Hossein A. Ghofrani</i> (Giessen, Germany)                         |
| 17:45 - 18:15 | <b>Panel discussion</b>  |





# FRIDAY, 10<sup>th</sup> June 2011

## 9:00 - 9:45 BEST POSTER PRESENTATION

	Chairs:	Philippe Menasché Felipe Prosper	(Paris, France) (Pamplona, Spain)
9:00 - 9:15	Prizes-giving		
9:15 - 9:30	Winner work presentation and discussion		
9:30 - 9:45	Winner work presentation and discussion		

## 9:45 - 11:50 RECENT CONTRIBUTIONS PRESENTED BY YOUNG INVESTIGATORS

	Chairs:	Philippe Menasché Felipe Prosper	(Paris, France) (Pamplona, Spain)
	Discussants:	Stefanie Dimmeler David García-Dorado Bernard Gersh John Martin James T. Willerson Kai C. Wollert	(Frankfurt, Germany) (Barcelona, Spain) (Rochester, USA) (London, UK) (Houston, USA) (Hannover, Germany)
9:45 - 10:00	<b>Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial dysfunction.</b> <i>Eckhard Alt</i> (MD Anderson group. Houston, USA)		
10:00 - 10:15	<b>Differential effects of progenitor cell population on left ventricular remodelling and myocardial neovascularisation after myocardial infarction</b> <i>Christophe Dubois</i> (Stefan Janssens' group. Leuven, Belgium)		
10:15 - 10:30	<b>Identification of new cardioactive paracrine factors by secretome analyses in patients undergoing cell therapy after myocardial infarction.</b> <i>Mortimer Korf-Klingebiel</i> (Kai C Wollert's group. Hannover, Germany)		
10:30 - 10:45	<b>Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair</b> <i>Xi-Ping Huang</i> (Toronto Research Institute Group. Toronto, Canada)		
10:45 - 11:00	<b>Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction</b> <i>Atta Behfar</i> (André Terzic's group. Rochester, USA)		
11:00 - 11:15	<b>Heart-derived cells for post-MI ventricular dysfunction</b> <i>Konstantinos Malliaras</i> (Eduardo Marban 's group. Los Angeles, USA)		

11:15 - 11:30 **Induced pluripotent stem cell (iPSC) - derived Flk-1 progenitor cells engraft, differentiate and improve heart function in a mouse model of acute myocardial infarction.**  
Robert Zweigerdt  
(Ulrich Martin's group. Hannover, Germany)

11:30 - 11:50 **Panel discussion**

## 11:50 - 12:10 **COFFEE BREAK**

---

## 12:10 - 13:40 **NEW DEVELOPMENTS AGAINST CARDIOVASCULAR DYSFUNCTION**

---

Chairs: Marisa Crespo (A Coruña, Spain)  
Arturo Fernández-Cruz (Madrid, Spain)

Discussants: Javier Castrodeza (Valladolid, Spain)  
Juan Carlos Chachques (Paris, France)  
Angel G. Pinto (Madrid, Spain)  
Manuel Sánchez-Luna (Madrid, Spain)  
Doris Taylor (Minneapolis, Madrid)

12:10 - 12:25 **Mechanics for heart replacement and preservation**  
Sharon Hunt (Stanford, USA)

12:25 - 12:40 **The revolution of cardiac valves replacement and repair**  
Magdi Yacoub (Harefield, UK)

12:40 - 12:55 **The future of biologic total and partial cardiac replacement. Will xenografts play a role?**  
Emanuele Cozzi (Padua, Italy)

12:55 - 13:20 **Surgical approaches to heart failure  
Lessons from the STICH trial**  
Bernard Gersh (Rochester, USA)

13:20 - 13:40 **Panel Discussion**

## 13:40 - 14:45 **LATE BREAKING CLINICAL TRIALS IN STEM CELL THERAPY - II**

---

Chairs: Stefan Janssens (Leuven, Belgium)  
José Suárez de Lezo (Córdoba, Spain)

Discussants: Bernard Gersh (Rochester, USA)  
Timothy Henry (Rochester, USA)  
Philippe Menasché (Paris, France)  
Aberto San Roman (Valladolid, Spain)  
James T. Willerson (Houston, USA)

- 13:40 – 13:55 **The APOLLO study**  
*Patrick Serruys* (Rotterdam, The Netherlands)
- 13:55 – 14:10 **The PRECISE study**  
*Emerson Perin* (Houston, USA)
- 14:10 – 14:25 **The TECAM study**  
*Francisco Fernandez-Aviles* (Madrid, Spain)
- 14:25 – 14:45 **Panel Discussion**

14:45 - 15:20 **CLOSING SESSION.**  
**FIGHTING THE SPECTRUM OF LEFT VENTRICULAR FAILURE**

---

Chairs: Rafael Matesanz (Madrid, Spain)  
Alberto San Román (Valladolid, Spain)

- 14:45 - 15:00 **Current status and future directions for cardiac cell repair therapy:  
The end of the beginning?**  
*Bernard Gersh* (Rochester, USA)
- 15:00 - 15:15 **The problem of end stage left ventricular dysfunction. Is bioartificial heart the answer?**  
*Doris Taylor* (Minnesota, USA)
- 15:15 - 15:20 **ADJOURN**  
*Francisco Fernández-Avilés* (Madrid, Spain)





SOCIEDAD  
ESPAÑOLA DE  
CARDIOLOGÍA

Comité de Acreditación  
CASEC

• Spanish Society of Cardiology.

Continuing Medical Education Accreditation Program. Activity accredited by the Spanish Society of Cardiology for 7.04 credit hours.



EBAC

• EBAC (European Board for Accreditation in Cardiology).

Activity accredited by the European Board for Accreditation in Cardiology for 10 CME credit hours.



• Comisión de Formación Continuada. Sistema Nacional de Salud

Activity accredited for 1.6 credit hours.

## DIRECTION

**Francisco Fernández-Avilés**

*Servicio de Cardiología*

*Hospital General Universitario Gregorio Marañón (Madrid, Spain)*

## CO-DIRECTION

**M<sup>a</sup> Eugenia Fernández Santos**

*Unidad de Producción Celular*

*Hospital General Universitario Gregorio Marañón (Madrid, Spain)*

**Bernard Gersh**

*Mayo Clinic (Rochester, USA)*

**John F. Martin**

*Centre for Cardiovascular Biology & Medicine (London, United Kingdom)*

**José Alberto San Román**

*Instituto de Ciencias del Corazón (ICICOR)*

*Hospital Clínico-Universitario de Valladolid (Valladolid, Spain)*

**Ana Sánchez**

*Instituto de Biología y Genética Molecular IBGM*

*Facultad de Medicina. Universidad de Valladolid (Valladolid, Spain)*

**Pedro L. Sánchez**

*Servicio de Cardiología*

*Hospital General Universitario Gregorio Marañón (Madrid, Spain)*

**Doris A. Taylor**

*Center for Cardiovascular Repair*

*University of Minnesota (Minneapolis, USA)*

**James T. Willerson**

*Texas Heart Institute (Houston, USA)*

## TECHNICAL DIRECTION

Ana Fernández Baza  
 Servicio de Cardiología  
 Hospital General Universitario Gregorio Marañón

## INTERNATIONAL SCIENTIFIC ADVISORY BOARD

Jozef Bartunek (Aalst, Belgium)	Anthony Mathur (London, United Kingdom)
Nabil Dib (San Diego, USA)	John Martin (London,, United Kigdom)
Stefanie Dimmeler (Frankfurt, Germany)	Philippe Menasche (Paris, France)
Valentín Fuster (New York, USA)	Bernardo Nadal-Ginard (Boston, USA)
Manuel Galiñanes (Leicester, United Kingdom)	Emerson Perin (Houston, USA)
Javier García-Sancho (Valladolid, Spain)	Doris Taylor (Minneapolis,USA)
Bernard Gersh (Rochester, USA)	William Wijns (Aalst, Belgium)
Juan Carlos Izpisúa (La Jolla, USA)	James T. Willerson (Houston, USA)
Stefan Janssens (Leuven, Belgium)	Andreas Zeiher (Frankfurt, Germany)

## EXECUTIVE LOCAL COMMITTEE

Carmen G. Morante	(Hospital G. Universitario Gregorio Marañón, Madrid)
Enrique Gutierrez	(Hospital G. Universitario Gregorio Marañón, Madrid)
Ricardo Sanz	(Hospital G. Universitario Gregorio Marañón, Madrid)
Adolfo Villa	(Hospital G. Universitario Gregorio Marañón, Madrid)

## ORGANIZATION

- Servicio de Cardiología. Hospital General Universitario Gregorio Marañón, Madrid.
- Instituto de Ciencias del Corazón (ICICOR). Hospital Clínico-Universitario de Valladolid
- Red Temática de Investigación Cardiovascular del Instituto de Salud Carlos III (RECAVA)
- Red Temática de Terapia Celular del Instituto de Salud Carlos III (TERCEL)
- Grupo de Terapia Celular Aplicada al Miocardio (TECAM, Hospital General Universitario Gregorio Marañón, Hospital Clínico-Universitario de Valladolid, Hospital Río Hortega, Instituto de Biología y Genética Molecular)
- Task Force on Stem Cell Regeneration of the Heart (European Society of Cardiology)

This symposium is aimed at both medical and non-medical scientists interested in the study and application of stem cell therapy and other biotechnological advances for the prevention and treatment of cardiovascular failure. For this reason the audience comprises:

- a. Preclinical researchers from all areas wishing to deepen their knowledge of cardiovascular biotechnological developments with therapeutic potential.
- b. Doctors specialising in the care of patients suffering from cardiovascular diseases, and who are interested in finding out about and discussing the current state of affairs and the future prospects for the application of these new therapeutic methods.
- c. Doctors involved in interventions dedicated to cardiovascular pathology and who are interested in the results and perspectives of gene vehiculization techniques, the stimulation of endogenous progenitors, cell transplant or electromechanical helps to fight cardiovascular disease.
- d. Medical or no medical professionals interested in the development of units and networks aimed at the translation of cardiovascular knowledge from bench to bedside and vice versa.
- e. Medical or no medical professionals interested in envisaging the opportunities for competition of biotechnology in the cardiovascular field

At the end of the conference those present will have acquired the following skills:

1. Knowledge and ability to discuss the latest advances in the role of progenitor cells in the integrity of the cardiovascular system of a healthy individual.
2. Knowledge and ability to discuss the latest experimental advances in the renewal and repair capacity of the damaged cardiovascular structure via the transplant of adult or embryonic stem cells or the stimulation of endogenous progenitors,.
3. Know about and be able to objectively debate the current state of feasibility, safety and efficacy with regards to the clinical application of cell therapy and other new biotechnological treatments.
4. Knowledge and ability to debate objectively on the efficiency of these types of treatment in patients with acute or chronic cardiovascular diseases.
5. Ability to predict the possibilities of scientific and professional attitude with regards to offering these therapeutic methods.
6. Ability to evaluate and decide one's own ability to participate in the application of these therapies for healthcare, clinical, and preclinical purposes.
7. Ability to identify those institutions and groups with the highest performance capabilities in these fields, and be able to establish contacts for educational, scientific, and healthcare purposes.

Eckhard Alt (Houston, USA)  
Stephen L. Archer (Chicago, USA)  
Xiaowen Bai (Houston, USA)  
Joan Albert Barberá (Barcelona, Spain)  
Josez Bartunek (Rochester, USA)  
Atta Behfar (Rochester, USA)  
Javier Bermejo (Madrid, Spain)  
Juan Carlos Chachques (Paris, France)  
Javier Castrodeza (Valladolid, Spain)  
Dominique Charron (Paris, France)  
Karen Christman (San Diego, USA)  
José Cortina (Madrid, Spain)  
Emanuele Cozzi (Padua, Italy)  
Marisa Crespo (A Coruña, Spain)  
Nabil Dib (San Diego, USA)  
Stefanie Dimmeler (Frankfurt, Germany)  
Christophe Dubois (Leuven, Belgium)  
Pilar Escribano (Madrid, Spain)  
Francisco Fernández-Avilés (Madrid, Spain)  
Arturo Fernandez Cruz (Madrid, Spain)  
Valentin Fuster (New York, USA)  
Angel G. Pinto (Madrid, Spain)  
Manuel Galiñanes (Barcelona, Spain)  
David García-Dorado (Barcelona, Spain)  
Bernard Gersh (Rochester, USA)  
Hossein A. Ghofrani (Giessen, Germany)  
Timothy Henry (Rochester, USA)  
Xi-Ping Huang (Toronto, Canada)  
Sharon Hunt (Stanford, USA)  
Stefan Janssens (Leuven, Belgium)  
Pilar Jimenez-Quevedo (Madrid, Spain)  
Mortimer Korf-Klingebiel (Hannover, Germany)  
Irene M. Lang (Vienna, Austria)  
Amir Lerman (Rochester, USA)  
Lilach Lerman (Rochester, USA)  
Ren-Ke Li (Toronto, Canada)  
Konstantinos Malliaras (Los Angeles, USA)  
Eduardo Marban (Los Angeles, USA)  
Anthony Marthur (London, UK)  
John Martin (London, UK)  
Rafael Matesanz (Madrid, Spain)  
Philippe Menasché (Paris, France)  
William McKenna (London, UK)  
María Orera (Madrid, Spain)  
Emerson Perin (Houston, USA)  
Felipe Prosper (Pamplona, Spain)

Luis Alonso Pulpon (Madrid, Spain)  
Mark S. Penn (Cleveland, USA)  
Alberto San Roman (Valladolid, Spain)  
Manuel Sánchez-Luna (Madrid, Spain)  
Julio Sandoval-Zárate (México DF, México)  
Patrick Serruys (Rotterdam, The Netherlands)  
Warren Sherman (New York, USA)  
Robert Simari (Rochester, USA)  
José Suárez de Lezo (Cordoba, Spain)  
Doris Taylor (Minnesota, USA)  
André Terzic (Rochester, USA)  
James T. Willerson (Houston, USA)  
Kai C. Wollert (Hannover, Germany)  
Magdi Yacoub (Harefield, UK)  
Andreas Zeiher (Frankfurt, Germany)  
Robert Zweigerdt (Hannover, Germany)



**MEETING VENUE**

Auditorium Consejo Superior de Investigaciones Científicas (CSIC)

C/ Serrano 117

28006 Madrid

**DATE**

9<sup>th</sup> and 10<sup>th</sup> June 2011

**OFFICIAL LANGUAGES**

English and Spanish (simultaneous translation will be available)

**TECHNICAL SECRETARIAT****Viajes Orbiazul**

C/ Alonso Pesquera, 2

47002 Valladolid

Tf. 00 34 983 30 91 92

Fx. 00 34 983 29 53 51

housing@cardiovascularcelltherapy.com

info@cardiovascularcelltherapy.com

The website [www.cardiovascularcelltherapy.com](http://www.cardiovascularcelltherapy.com) is a virtual place which contains all the information related to this Symposium and its previous editions

It is possible through this web-site to access the scientific program, to register and to reserve accommodation.

It is also a priority for this web site to offer updated information about Stem Cell Therapy for Cardiovascular Diseases, so that appropriate access to the related sites has been created.

You can also join us on **Facebook** and **Twitter**.







**DIRECTION**

**Francisco Fernández-Avilés**

*Servicio de Cardiología*

*Hospital General Universitario Gregorio Marañón (Madrid, Spain)*

**CO-DIRECTION**

**M<sup>a</sup> Eugenia Fernández Santos**

*Unidad de Producción Celular*

*Hospital General Universitario Gregorio Marañón (Madrid, Spain)*

**Bernard Gersh**

*Mayo Clinic (Rochester, USA)*

**John F. Martin**

*Centre for Cardiovascular Biology & Medicine (London, United Kingdom)*

**José Alberto San Román**

*Instituto de Ciencias del Corazón (ICICOR)*

*Hospital Clínico-Universitario de Valladolid (Valladolid, Spain)*

**Ana Sánchez**

*Instituto de Biología y Genética Molecular IBGM*

*Facultad de Medicina. Universidad de Valladolid (Valladolid, Spain)*

**Pedro L. Sánchez**

*Servicio de Cardiología*

*Hospital General Universitario Gregorio Marañón (Madrid, Spain)*

**Doris A. Taylor**

*Center for Cardiovascular Repair*

*University of Minnesota (Minneapolis, USA)*

**James T. Willerson**

*Texas Heart Institute (Houston, USA)*

**TECHNICAL DIRECTION**

Ana Fernández Baza

**Hospital General Universitario Gregorio Marañón**

*C/ Doctor Esquerdo, 46. 28007 Madrid*

*T. 00 34 91 426 58 82 / F. 00 34 91 586 82 76*

*anafdez baza@cardiovascularcelltherapy.com*

**TECHNICAL SECRETARIAT**

Viajes Orbiazul

*C/ Alonso Pesquera 2. 47002 Valladolid*

*T. 00 34 983 30 91 22 / F. 00 34 983 29 53 51*

*housing@cardiovascularcelltherapy.com*